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ABSTRACT 
Background and Objectives: Heart failure rarely occurs in patients with thyrotoxicosis (6%), with half of the cases 
having left ventricular dysfunction (LVD). Although a few studies reported isolated right heart failure in thyro-
toxicosis, there has been no evaluation of relationship between LVD and right ventricular dysfunction (RVD). Sub-
jects and Methods: We enrolled 12 patients (mean age: 51±11 years, 9 females) diagnosed as having thyrotoxi-
cosis with heart failure and LVD {left ventricular ejection fraction (LVEF) <40%}, and divided them into two 
groups {Group I with RVD defined as tricuspid annular plane excursion (TAPSE) less than 15 mm and Group II 
without RVD}. Clinical features, laboratory variables, and echocardiographic parameters were compared between 
two groups. Results: RVD was found in 6 (50%) patients. On admission, there were no significant differences be-
tween the two groups in clinical features, laboratory variables, or echocardiographic parameters including atrial 
fibrillation {6 vs. 5, not significant (NS)}, heart rate (149±38 vs. 148±32/min, NS), LVEF (36.7±9.5 vs. 35.1±
6.3%, NS), or the tricuspid regurgitation peak pressure gradient (TRPPG, 30.9±2.0 vs. 36.3±9.3 mmHg, NS). 
After antithyroid treatment, all achieved an euthyroid state and both ventricular functions were recovered. All data, 
including the recovery time of LVEF and the change of heart rate between two groups, displayed no significant 
differences. Conclusion: In half of patients, RVD was combined with thyrotoxicosis-associated LVD. There were 
no differences in clinical factors or hemodynamic parameters between patients with and without RVD. This sug-
gests that RVD is not secondary to thyrotoxicosis-associated LVD. (Korean Circ J 2010;40:266-271) 
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Introduction 
 
Thyrotoxicosis can be manifested by many cardiovas-
cular symptoms including palpitation, exercise intoler-
ance, dysrhythmia, systolic hypertension, cardiomegaly, 
peripheral edema, and angina.
1) Over 90% of patients 
experience tachycardia, and 10% experience atrial fibrill-
ation or atrial flutter. In addition, chronic or severe th-
yrotoxicosis can aggravate sinus tachycardia or atrial fi-
brillation and cause heart failure accompanied by left 
ventricular systolic dysfunction.
1-3) Heart failures by this 
mechanism have been explained as tachycardia-induced 
cardiomyopathy in previous studies.
4) 
Recently, it has been reported that thyrotoxicosis is 
presented first as right ventricular failure accompany-
ing pulmonary artery hypertension and tricuspid regur-
gitation.
5) However, most studies on right ventricular 
dysfunction (RVD) related to thyrotoxicosis mention only 
isolated right ventricular failure,
6-11) and there are almost 
no studies on about wheather both left ventricular dys-
function (LVD) and right ventricular failure occur si-
multaneously, or there is correlation between the two. 
Therefore, to the purpose of this study was to identify 
factors that affect right ventricular systolic dysfunction 
occurring in thyrotoxicosis, and particularly examine 
whether RVD is related to LVD by tachycardia-induc-
ed cardiomyopathy occurring in thyrotoxicosis patients. 
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Subjects and Methods 
 
Subjects 
This research is a retrospective study on 12 patients 
diagnosed with thyrotoxicosis and LVD {left ventricle 
ejection fraction (LVEF) <40%}. Among the patients 
(male：female=3：9, mean age=51±11) that were ad-
mitted to Kangdong Sacred Heart Hospital of Hallym 
University College of Medicine for heart failure be-
tween September 2005 to October 2007, 9 were diag-
nosed with thyrotoxicosis for the first time and 3 were 
diagnosed in previous years, but not treated. In addit-
ion, coronary artery disease, hypertension, valvular heart 
disease, drug use, and infection were ruled out as causes 
of LVD. 
 
Methods 
The 12 patients diagnosed with thyrotoxicosis and 
LVD were divided into a group (group 1) with RVD and 
a group (group 2) without RVD by using tricuspid an-
nular plane excursion (TAPSE). The TAPSE estimated 
RV systolic function by measuring the level of systolic 
excursion of the lateral tricuspid valve annulus towards 
the apex in the four chamber view. If the measured TA-
PSE was 15 mm or shorter, a patient was was defined 
as having RVD (group 1), and if it was 15 mm or longer, 
the patient was defined as non-RVD (group 2). 
The sex, age, and clinical conditions, including the 
presence of underlying diseases and heart rates, echo-
cardiographic findings, blood tests including troponin, 
B-type natriuretic peptide (BNP), and thyroid function 
tests at the time of admission were compared between 
2 groups. In addition, when the two groups achieved an 
euthyroid state after antityhroid therapy, the clinical con-
dition, echocardiographic parameters and blood treats 
were compared between two groups. 
Left atrial dimension, diastolic left ventricular dimen-
sion, LVEF, diastolic right ventricular dimension, maxi-
mum pressure difference of tricuspid regurgitation, and 
postcaval dimension were measured with the use of tr-
ansthoracic echocardiography. As for left atrial dimen-
sion, maximal anteroposterior length was measured by 
M-mode echocardiography at the aortic level of the pa-
rasternal short axis view. Diastolic left ventricular di-
mensions were measured immediately before the QRS 
of an electrocardiogram with M-mode echocardiogra-
phy at the parasternal short axis view. The right ven-
tricular anteroposterior dimension was measured at the 
end of systole when right ventricular volume reached 
its maximum in the parasternal long axis view. While the 
inferior vena cava (IVC) dimension can be measured at 
a subcostal window, the widest length at exhalation was 
selected. Tricuspid regurgitation (TR) was classified into 
mild, moderate, or severe by measuring the degree of re-
gurgitation. Mild TR is defined as when regurgitation 
past the tricuspid valve reaches 1/3 entire distance of ri-
ght atrium but not 1/2; moderate TR as when the regur-
gitation reaches 1/2 the distance but not 2/3; and se-
vere TR as when regurgitation reaches beyond 2/3 the 
distance, nearly to the rear wall of the right atrium. 
 
Statistical analysis 
For statistical analysis, Statistical Package for the So-
cial Sciences (SPSS) 12.0 (SPSS Inc., Chicago, IL, USA) 
software for Windows was used. All data are presented 
in mean±standard deviation, and for discontinuous 
variables between the two groups, the chi square test and 
the Mann-Whitney test were used. In order to determine 
changes in clinical status, blood tests and echocardio-
graphic indicators at the time of admission and after 
treatment of thyrotoxicosis, the Wilcoxon signed rank 
test was performed. Values were considered significant 
if the p was less than 0.05. 
 
Results 
 
Clinical characteristics (Table 1) 
The mean age of all patients was 51±11, and there 
were more female (n=9, 75%) patients than male. Three 
patients had diabetes, hypertension or cerebrovascular 
disease; 3 patients smoked; and 2 patients had a history 
of alcohol use. Eleven patients showed atrial fibrillation 
with tachycardia, and the remaining patient showed si-
nus tachycardia with a heart rate of 150/min. The cause 
of thyrotoxicosis in 11 patients was Graves’ disease, and 
1 patient had suspected thyroid follicular adenomatosis. 
Six patients showed RVD (50%), and clinical characte-
ristics between the two groups were not significantly dif-
ferent. Two patients underwent coronary angiography 
to rule out ischemic heart disease while hospitalized, and 
both belonged to RVD group. Neither had any lesions in 
the coronary artery, but one patient showed coronary vas-
ospasm and the another showed myocardial bridging 
findings. 
 
Blood test 
There was no significant difference found between 
the two groups in any blood tests obtained at admission, 
including free thyroxine (free T4), triiothyronine (T3), 
BNP, troponin, creatine kinase-MB (CK-MB) and C-
reactive protein (CRP). Group 1 showed higher low den-
sity lipoprotein-cholesterol level compared with group 2, 
but the difference was not statistically significant (p= 
0.055). Serum creatinine values were significantly higher 
in group 1 (p<0.05), but mean value was within normal 
range (Table 2). 
There was no significant difference between the two 
groups in tests for anti-thyroglobulin autoantibody, anti-
thyroid peroxidase antibody (TPOAb) and thyroid stimu-
lating hormone receptor antibody (TSHRAb) (Table 3).  
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Echocardiography (Table 4) 
There were no statistically significant differences be-
tween the two groups in the results of echocardiography 
on the left atrial dimension, diastolic left ventricular 
dimension, LVEF, diastolic right ventricular dimension, 
the maximum pressure gradient of TR, or the IVC dimen-
sion. In the RVD group, the diastolic right ventricular 
dimension tended to be greater than normal group, but 
the difference was not statistically significant (p=0.078). 
 
Results after antithyroid drug treatment 
All patients took propylthiouracil (PTU) as antithy-
roid drug agent, and the free T4 and T3 values of all 
patients reached normal levels in an average of 85.8±
70.5 days, this was a statistically significant change (Fig. 
1). The 11 patients that showed atrial fibrillation with 
Table 1. Characteristics of all patients on admission 
  All (n=12)  Group I (TAPSE ≤15) (n=6)  Group II (TAPSE >15) (n=6)  p
Age (years)  51±11  50±6  52±3  0.936
Female  09 (75)  4 (67)  9 (84)  0.523
Hypertension  01 (8)  0 (0)  1 (16)  0.317
Diabetes mellitus  01 (8)  1 (16)  0 (0)  0.317
Cerebral vascular disease  01 (8)  1 (16)  0 (0)  0.317
Smoking history  03 (25)  2 (25)  1 (16)  0.902
Alcohol history  02 (16.3)  1 (16.3)  1 (16)  0.523
Etiology of hyperthyroidism         
Graves’ disease  11 (92)  6 (100)  5 (82)  0.317
Others  01 (8)  0 (0)  1 (16)  0.317
SBP (mmHg)  123±26  122±19  148±32  0.747
DBP (mmHg)  78±19  78±14  77±24  0.511
AF on admission  11 (92)  6 (100)  5 (82)  0.317
HR at admission (bpm)  149±33  149±38  148±32  0.784
Values are in n (%) or mean±standard deviation. TAPSE: tricuspid annular plane excursion, SBP: systolic blood pressure, DBP: diastolic blood
pressure, AF: atrial fibrillation, HR: heart rate 
 
Table 2. Comparison of laboratory data between the 2 groups on admission
  All (n=12)  Group I (TAPSE ≤15) (n=6)  Group II (TAPSE >15) (n=6)  p
CBC         
WBC (/uL)  8,841±4,646  8,096±3,778  9,586±5,641  0.873
Hb (g/dL)  13±2  14±2  12±1  0.092
Creatinine  0.7±0.3  0.9±0.3  0.5±0.1  0.041
Total cholesterol (mg/dL)  101±47  117±57  86±32  0.337
TG (mg/dL)  65±56  83±72  47±31  0.200
LDL-C (mg/dL)  56±29  71±31  41±19  0.055
Thyroid Function test         
T3 (ng/dL)  425±245  397±287  453±219  0.688
Free T4 (ng/dL)  5.4±3.1  4.6±3.2  6.2±3.1  0.337
CRP (mg/L)  10.4±10.3  7.5±5.3  13.2±13.8  0.465
ESR (mm/hr)  4.0±4.7  4.8±5.8  2.7±4.6  0.759
Troponin I (ng/mL)  0.08±0.06  0.05±0.03  0.1±0.11  0.784
BNP (pg/mL)  724±392  610±431  819±369  0.201
CK-MB (ng/mL)  1.7±1.0  1.8±1.1  1.6±1.0  0.715
Values are in n (%) or mean±standard deviation. TAPSE: tricuspid annular plane excursion, WBC: white blood cell, Hb: hemoglobin, TG: tri-
glyceride, LDL-C: low density lipoprotein-cholesterol, T3: triiodothyronine, Free T4: free thyroxine, CRP: C-reactive protein, ESR: erythrocyte 
sedimentation rate, BNP: B-type natriuretic peptide, CK-MB: creatine kinase-MB, CBC: complete blood count 
 
Table 3. Comparison of anti-thyroid antibodies between the 2 groups on admission
  Total (%)  Group I (TAPSE ≤15) (%)  Group II (TAPSE >15) (%)  p
TSHRAb (%)  45.7±21.7  37.2±20.2  60.0±20.6  0.1 
Anti TPO (+)  6 (60)  2 (40)  4 (80)  0.524
Anti TG (+)  2 (28.7)  0 (0)  2 (50)  0.429
Values are in n (%) or mean±standard deviation. TAPSE: tricuspid annular plane excursion, TSHRAb: thyroid stimulating hormone receptor 
antibody, Anti TPO: anti peroxidase antibody, Anti TG: anti thyroglobulin antibody 
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tachycardia showed a significant decrease of heart rate 
from 149.3/min to 75.1/min in average, and two pa-
tients were converted to normal sinus rhythm (Fig. 2). 
LVEF and TAPSE were improved over 40% and 15 mm 
respectively in an average of 61.1±66.5 days, also a st-
atistically significantly increase (Fig. 2). TR was signifi-
cantly improved as thyroid function returned to nor-
mal (Table 6). However no significant differences were 
found in blood pressure, BNP, diastolic left ventricular 
dimension, right ventricular dimension, the maximal 
pressure gradient of TR, or the IVC after treatment. 
When the two groups were compared after restora-
tion to normal thyroid function, clinical parameters in-
cluding blood pressure and heart rate did not show a 
significant difference, nor did echocardiographic para-
meters, the thyroid function test (free T4, T3), BNP, 
left atrial dimension, LVEF, diastolic right ventricular 
dimension, the maximal pressure gradient of TR, or the 
IVC dimension (Table 5). 
 
Discussion 
 
Thyroid hormone (particularly T3) increases heart rate 
and left ventricular contractility, decreases systemic vas-
Table 4. Comparison of echocardiographic parameters between the 2 groups on admission
  All (n=12)  Group I (TAPSE ≤15) (n=6)  Group II (TAPSE >15) (n=6)  p
LA (mm)  43.7±6.4  44.3±3.6  43.2±8.7  0.748
LVDd (mm)  51.8±5.8  51.5±5.2  52.2±6.9  0.936
LVEF (%)  35.9±7.7  36.7±9.5  35.1±6.3  0.630
RVd (mm)  31.5±8.9  35.8±8.3  27.2±7.9  0.078
TRPPG (mmHg)  33.6±7.0  30.9±2.0  36.3±9.3  0.197
IVCd (mm)  20.4±4.9  19.6±2.2  21.3±4.6  0.296
Values are in n (%) or mean±standard deviation. TAPSE: tricuspid annular plane excursion, LA: left atrium, LVDd: left ventricular end 
diastolic diameter, LVEF: left ventricular ejection fraction, RVd: right ventricular diameter, TRPPG: tricuspid regurgitation peak pressure gra-
dient, IVCd: inferior vena cava diameter 
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Fig. 1. Comparisons of T3, free T4, and heart rate between admission and conversion to the euthyroid state. T3: triiodothyronine, free T4:
free thyroxine. 
Fig. 2. Comparison of TAPSE and LVEF between admission and conversion to the euthyroid state. TAPSE: tricuspid annular plane excurs-
ion, LVEF: left ventricular ejection fraction. 
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cular resistance, increases sodium re-absorption and ery-
thropoietin secretion, and raises stroke volume up to 
300%.
1) However, during thyrotoxicosis, atrial fibrilla-
tion or sinus tachycardia can occur, which may be caused 
by a calcium circulation distrubance to heart cells and 
structural changes in the heart.
1-3) In case that atrial fi-
brillation or sinus tachycardia lasts for an extended pe-
riod due to uncontrolled thyrotoxicosis, 6% of the pa-
tients experience heart failure, and among these cases 
half are accompanied by LVD; this is termed tachycar-
dia induced cardiomyopathy.
3)4) 
Recently, a few studies have reported that thyrotoxi-
cosis is manifested first by right heart failure with pul-
monary artery hypertension and tricuspid regurgitation, 
but only isolated right ventricular failure was mention-
ed,
7-12) and no study has been reported in which both 
RVD and LVD occur simultaneously. The purpose of 
this study is to determine the causative factors that trigger 
RVD in thyrotoxicosis and to examine the relationship 
between RVD and LVD in tachycardia induced cardio-
myopathy. 
Among the patients that experienced LVD by thyro-
toxicosis, half (50%) had RVD. All 12 patients showed 
improvement in clinical features, blood tests, and echo-
cardiography after thyrotoxicosis treatment. On admis-
sion, the RVD group (group 1) and the non-RVD group 
(group 2) did not show any significant differences in 
blood tests or clinical features including heart rate and 
BNP. Echocardiographic parameters also did not show 
any significant differences between the two groups. 
Even in the euthyroid state, there was no significant 
difference between the two groups in the results of all 
tests, including changes in heart rate and the change of 
LVEF. That suggests that RVD occuring in thyrotoxico-
sis patients experiencing LVD has a different mecha-
nism, compared with tachycardia induced cardiomyo-
pathy known as mechanism of right heart failure in th-
yrotoxicosis. 
If RVD in thyrotoxicosis is not caused by a secon-
dary change in tachycardia-induced cardiomyopathy or 
secon-dary pulmonary artery hypertension, the right 
ventricle itself may be considered as the cause of RVD. 
Research indicating that the direct application of thy-
roid hormone to myocardial cells causes toxic effects has 
been explained by myocardial stunning.
13)14) In addition, 
Kiss et al.
15) found that the function of calcium ions 
within myocardial cells is deteriorated in thyrotoxicosis 
patients, and demonstrated that thyroid hormone af-
fects transcription within myocardial cells and inhibits 
the synthesis of required proteins, triggering heart fail-
ure.
16) In practice, thyroid hormone is known to affect 
many ion channels in the myocardial cell membrane, 
as well as gene expression within the nucleus of the myo-
cardial cell.
2) However, as thyroid hormone affects all 
myocardial cells and is not specific to the right ventricle, 
this data is not sufficient to explain the cause of RVD 
dysfunction. We hypothesize that when exposed to thy-
roid hormone, sensitivity of thyroid hormone receptor 
(TR) isomers TRα1, TRα2, and TRβ1 within myo-
cardial cell changes; this mayalter the effects of thyroid 
hormone and explain the mechanism of RVD.
1)2) 
Table 5. Comparison of clinical features, laboratory data, 2-dimensional echocardiographic parameters between the two groups in the eu-
thyroid state 
  Total  Group I (TASPE ≤15)  Group II (TAPSE >15)  p
Time to euthyroid state (days)  85.7±70.5  70.0±68.2  104.6±76.2  0.465
Time to normal LVEF (days)  61.1±66.5  51.3±64.4  70.8±73.1  0.873
ΔSBP (mmHg)  27.9±25.7  23.3±17.5  32.5±33.1  0.744
ΔDBP (mmHg)  18.3±19.0  15.0±17.6  21.7±21.4  0.566
HR  Δ bpm  72.9±27.0  72.6±35.6  73.2±23.5  0.855
Free T4 (ng/dL) Δ   3.4±3.1  2.7±2.8  4.3±3.6  1 
T3 (ng/dL) Δ   167.1±170.6  176.5±164.8  161.8±201.5  0.361
BNP (pg/mL) Δ   374.5±413.6  394.9±515.9  347±334.6  0.201
LA (mm) Δ   2.2±5.3  1.8±5.9  2.7±5.2  0.809
RVd (mm) Δ   7.2±3.9  7.7±3.5  6.8±4.5  0.744
TRPPG (mmHg) Δ   5.2±4.8  4.5±5.6  6.0±4.0  0.273
IVCd (mm) Δ   5.8±3.6  7.4±2.6  4.2±3.9  0.249
Values are mean±standard deviation. Δ: change from admission to the euthyroid state, LVEF: left ventricular ejection fraction, SBP: systolic 
blood pressure, DBP: diastolic blood pressure, HR: heart rate, free T4: free thyroxine, T3: triiodothyronine, BNP: B-type Natriuretic Peptide, 
LA: left atrium, RVd: right ventricular diameter, TRPPG: tricuspid regurgitation peak pressure gradient, IVCd: inferior vena cava diameter, 
TAPSE: tricuspid annular plane excursion 
 
Table 6. Comparison of tricuspid regurgitation between admiss-
ion and conversion to the euthyroid state (p=0.02) 
TR severity  Admission (n=12)  Euthyroid state (n=11)
Trace 0  1 
Mild 7  9 
Moderate 3  1 
Severe 2  0 
TR: tricuspid regurgitation 
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The limitation of this research is that we only studied 
12 patients, so it is hard to draw statistically significant 
conclusions. However, only few case reports have been 
presented on thyrotoxicosis and right heart failure, and 
even in the largest study, performed by Cohen and Sch-
attner
7) only 8 patients were examined. In addition, since 
this is a retrospective study, cardiac catheterization for the 
accurate measurement of pulmonary artery pressure was 
not performed. 
In conclusion, we demonstrate that RVD occurring in 
thyrotoxicosis is not related to secondary hemodynamic 
change by left ventricular systolic dysfunction. We hypo-
thesize there may be a direct toxic effect of thyroid hor-
mone on right ventricle, but further study is needed to 
validate this idea. However, we believe it is reasonable 
given that thyroid hormone affects gene expression in 
the nuclear of myocardial cells and works on various ion 
channels existing in the myocardial cell membrane. A 
sensitivity difference to thyroid hormone within cells 
could affect right heart failure. I think it is needed fur-
ther study about molecular biology. 
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